This collaborative project is an extension of the 2016 End of Term project, intended to document the federal government's web presence by archiving government websites and data. As part of this preservation effort, URLs supplied from partner institutions, as well as nominated by the public, will be crawled regularly to provide an on-going view of federal agencies' web and social media presence. Key partners on this effort are the Environmental Data & Governance Initiative and the Data Refuge project. This collection is a continuation of the 2016 End of Term web archiving and, as such, is deduplicated against that collection. It allows for the ongoing archiving of publicly nominated websites beyond the "official" end of the End of Term project. 
 
 Interested members of the public, particularly government information specialists, are invited to submit selected web sites to be included in the collection using the public nomination tool. 
 
 For more information on partner institutions, web crawling and past End of Term projects, please visit the End of Term Archive. ||||| Shares of Ariad Pharmaceuticals plunged as much as 15 percent after Sen. Bernie Sanders criticized the price of the company's leukemia drug on Twitter. 
 
 
 
 The stock ended the day down about 14.8 percent at $11.14 a share. 
 
 In a statement, Ariad said, "our pricing reflects our significant investment in R&D, our commitment to the very small, ultra orphan cancer patient populations that we serve and the associated risk with research and development." 
 
 The company added that it spent 143 percent of its total revenue in 2015 in research and development for treatments of rare cancers. 
 
 
 

– A single tweet from Bernie Sanders was enough to send the share price of Ariad Pharmaceuticals Inc. to dive 15% Friday, wiping around $387 million off the value of the drug firm, the Hill reports. "Drug corporations’ greed is unbelievable. Ariad has raised the price of a leukemia drug to almost $199,000 a year," Sanders tweeted, linking to this article about the Massachusetts-based firm, which has raised the price of its Iclusig medication four times this year. "Our pricing reflects our significant investment in R&D, our commitment to the very small, ultra orphan cancer patient populations that we serve and the associated risk with research and development," the company said in a statement, adding that its R&D cost was more than its revenue last year. CNBC notes that this has been a tough year for the biotech sector, with overall share prices down more than 20% amid strong criticism on the campaign trail. But Ariad shareholders aren't going to lose their shirts: Even with Friday's drop, the company's share price is still up 78% this year.